71 related articles for article (PubMed ID: 33618175)
21. Blocking of FGFR4 signaling by F30 inhibits hepatocellular carcinoma cell proliferation through HMOX1-dependent ferroptosis pathway.
Huang F; Shi X; Hu M; Yan H; Li X; Ding Y; Zheng X; Cai X; Dai S; Xia Q; Cai Y
Eur J Pharmacol; 2024 May; 970():176493. PubMed ID: 38484925
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of novel N1-acylated 5-(4-pyridinyl)indazole derivatives as potent and selective haspin inhibitors.
Shawky MM; Abdallah M; Khalifa H; Aboushady Y; Abadi AH; Engel M; Abdel-Halim M
Bioorg Chem; 2024 Apr; 145():107235. PubMed ID: 38447464
[TBL] [Abstract][Full Text] [Related]
23. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression.
Liu Y; Cao M; Cai Y; Li X; Zhao C; Cui R
Front Cell Dev Biol; 2020; 8():95. PubMed ID: 32154250
[TBL] [Abstract][Full Text] [Related]
24. Synthesis of 3-[(N-carboalkoxy)ethylamino]-indazole-dione derivatives and their biological activities on human liver carbonyl reductase.
Berhe S; Slupe A; Luster C; Charlier HA; Warner DL; Zalkow LH; Burgess EM; Enwerem NM; Bakare O
Bioorg Med Chem; 2010 Jan; 18(1):134-41. PubMed ID: 19959367
[TBL] [Abstract][Full Text] [Related]
25. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
[No Abstract] [Full Text] [Related]
26. AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest.
Zhou W; Lou W; Chen J; Ding B; Chen B; Xie H; Zhou L; Zheng S; Jiang D
Onco Targets Ther; 2021; 14():1049-1059. PubMed ID: 33623392
[TBL] [Abstract][Full Text] [Related]
27. Discovery of a novel AR/HDAC6 dual inhibitor for prostate cancer treatment.
Zhou M; Zheng H; Li Y; Huang H; Min X; Dai S; Zhou W; Chen Z; Xu G; Chen Y
Aging (Albany NY); 2021 Feb; 13(5):6982-6998. PubMed ID: 33621955
[TBL] [Abstract][Full Text] [Related]
28. Pirfenidone inhibits fibroblast proliferation, migration or adhesion and reduces epidural fibrosis in rats via the PI3K/AKT signaling pathway.
Zhang X; Zhang J; Liu Y; Zhu D; Chen D; Zhang Z; Sun Y
Biochem Biophys Res Commun; 2021 Apr; 547():183-191. PubMed ID: 33618225
[TBL] [Abstract][Full Text] [Related]
29. Targeting FGFR in non-small cell lung cancer: implications from the landscape of clinically actionable aberrations of FGFR kinases.
Zhou Z; Liu Z; Ou Q; Wu X; Wang X; Shao Y; Liu H; Yang Y
Cancer Biol Med; 2021 Mar; 18(2):490-501. PubMed ID: 33710807
[TBL] [Abstract][Full Text] [Related]
30. CD44 modulates metabolic pathways and altered ROS-mediated Akt signal promoting cholangiocarcinoma progression.
Thanee M; Dokduang H; Kittirat Y; Phetcharaburanin J; Klanrit P; Titapun A; Namwat N; Khuntikeo N; Wangwiwatsin A; Saya H; Loilome W
PLoS One; 2021; 16(3):e0245871. PubMed ID: 33780455
[TBL] [Abstract][Full Text] [Related]
31. Ligand based 3D-QSAR model, pharmacophore, molecular docking and ADME to identify potential fibroblast growth factor receptor 1 inhibitors.
Huang L; Wu X; Fu X; Wang H; Tang B; Xiao Y; Zhou C; Zhao Z; Wan Y; Chen H; Tang Z; Yao H; Shan Z; Bu T
J Biomol Struct Dyn; 2022 Oct; 40(16):7584-7597. PubMed ID: 33734039
[TBL] [Abstract][Full Text] [Related]
32. Recurrent cholangiocarcinoma with long-term survival by multimodal treatment: A case report.
Sota Y; Einama T; Kobayashibayashi K; Fujinuma I; Tsunenari T; Takihata Y; Iwasaki T; Miyata Y; Okamoto K; Kajiwara Y; Shinto E; Tsujimoto H; Yasuda S; Isozaki Y; Yamada S; Yamamoto J; Ueno H; Kishi Y
Mol Clin Oncol; 2021 Apr; 14(4):72. PubMed ID: 33732458
[TBL] [Abstract][Full Text] [Related]
33. The Co-mutational Spectrum Determines the Therapeutic Response in Murine FGFR2 Fusion-Driven Cholangiocarcinoma.
Kendre G; Marhenke S; Lorz G; Becker D; Reineke-Plaaß T; Poth T; Murugesan K; Kühnel F; Woller N; Wirtz RM; Pich A; Marquardt JU; Saborowski M; Vogel A; Saborowski A
Hepatology; 2021 Sep; 74(3):1357-1370. PubMed ID: 33709535
[TBL] [Abstract][Full Text] [Related]
34. Typing FGFR2 translocation determines the response to targeted therapy of intrahepatic cholangiocarcinomas.
Pu X; Ye Q; Cai J; Yang X; Fu Y; Fan X; Wu H; Chen J; Qiu Y; Yue S
Cell Death Dis; 2021 Mar; 12(3):256. PubMed ID: 33692336
[TBL] [Abstract][Full Text] [Related]
35. The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma.
Kanzaki H; Chiba T; Ao J; Koroki K; Kanayama K; Maruta S; Maeda T; Kusakabe Y; Kobayashi K; Kanogawa N; Kiyono S; Nakamura M; Kondo T; Saito T; Nakagawa R; Ogasawara S; Suzuki E; Ooka Y; Muroyama R; Nakamoto S; Yasui S; Tawada A; Arai M; Kanda T; Maruyama H; Mimura N; Kato J; Zen Y; Ohtsuka M; Iwama A; Kato N
Sci Rep; 2021 Mar; 11(1):5303. PubMed ID: 33674622
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment.
Liu G; Chen T; Ding Z; Wang Y; Wei Y; Wei X
Cell Prolif; 2021 Apr; 54(4):e13009. PubMed ID: 33655556
[TBL] [Abstract][Full Text] [Related]
37. 1
Donaire-Arias A; Montagut AM; Puig de la Bellacasa R; Estrada-Tejedor R; Teixidó J; Borrell JI
Molecules; 2022 Mar; 27(7):. PubMed ID: 35408636
[TBL] [Abstract][Full Text] [Related]
38. (Trifluoromethoxy)Phenylboronic Acids: Structures, Properties, and Antibacterial Activity.
Adamczyk-Woźniak A; Gozdalik JT; Kaczorowska E; Durka K; Wieczorek D; Zarzeczańska D; Sporzyński A
Molecules; 2021 Apr; 26(7):. PubMed ID: 33916124
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Covalent Warheads in the Design of 2-Aminopyrimidine-based FGFR4 Inhibitors.
Deng W; Chen X; Jiang K; Song X; Huang M; Tu ZC; Zhang Z; Lin X; Ortega R; Patterson AV; Smaill JB; Ding K; Chen S; Chen Y; Lu X
ACS Med Chem Lett; 2021 Apr; 12(4):647-652. PubMed ID: 33859803
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and biological evaluation of indazole derivatives as selective and potent FGFR4 inhibitors for the treatment of FGF19-driven hepatocellular cancer.
Chen X; Liu Y; Zhang L; Chen D; Dong Z; Zhao C; Liu Z; Xia Q; Wu J; Chen Y; Zheng X; Cai Y
Eur J Med Chem; 2021 Mar; 214():113219. PubMed ID: 33618175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
